These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 28858531

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis.
    Tafazzoli A, Chavan A, Harty G, Moller J, Wong SL.
    Adv Ther; 2020 Sep; 37(9):3791-3806. PubMed ID: 32647909
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
    Rammohan K, Coyle PK, Sylvester E, Galazka A, Dangond F, Grosso M, Leist TP.
    Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
    [Abstract] [Full Text] [Related]

  • 25. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
    Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z.
    Acta Neurol Scand; 2004 Jun; 109(6):390-2. PubMed ID: 15147461
    [Abstract] [Full Text] [Related]

  • 26. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study.
    Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M, Grieb P.
    Mult Scler; 2009 Jun; 15(6):767-70. PubMed ID: 19482866
    [Abstract] [Full Text] [Related]

  • 27. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.
    Oh J, O'Connor PW.
    CNS Drugs; 2013 Aug 04; 27(8):591-609. PubMed ID: 23801528
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Oral cladribine and fingolimod for relapsing multiple sclerosis.
    Li H, Zhang X.
    N Engl J Med; 2010 May 06; 362(18):1738-9; author reply 1739-40. PubMed ID: 20449878
    [No Abstract] [Full Text] [Related]

  • 35. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A, Pogoda-Wesołowska A, Tokarz-Kupczyk E, Słowik A, Puz P, Adamczyk-Sowa M, Kurkowska-Jastrzębska I, Kułakowska A, Chorąży M, Piasecka-Stryczyńska K, Jamróz-Wiśniewska A, Bartosik-Psujek H, Rejdak K.
    Neurol Neurochir Pol; 2023 May 06; 57(4):371-378. PubMed ID: 37490356
    [Abstract] [Full Text] [Related]

  • 36. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A, CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.
    Clin Drug Investig; 2012 Jan 01; 32(1):15-27. PubMed ID: 22017519
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P.
    Mult Scler; 2019 May 01; 25(6):819-827. PubMed ID: 29716436
    [Abstract] [Full Text] [Related]

  • 38. Oral treatment for multiple sclerosis.
    Killestein J, Rudick RA, Polman CH.
    Lancet Neurol; 2011 Nov 01; 10(11):1026-34. PubMed ID: 22014437
    [Abstract] [Full Text] [Related]

  • 39. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K.
    Mult Scler; 2018 Oct 01; 24(11):1461-1468. PubMed ID: 28817997
    [Abstract] [Full Text] [Related]

  • 40. Development of oral cladribine for the treatment of multiple sclerosis.
    Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC.
    J Neurol; 2010 Feb 01; 257(2):163-70. PubMed ID: 19921304
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.